about
Evidence that Aurora B is implicated in spindle checkpoint signalling independently of error correction.How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studiesThe PAR complex controls the spatiotemporal dynamics of F-actin and the MTOC in directionally migrating leukocytes.Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors.Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.Update on medical treatment of small intestinal neuroendocrine tumors.Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up.Adaptation to the spindle checkpoint is regulated by the interplay between Cdc28/Clbs and PP2ACdc55Cells Escape an Operational Mitotic Checkpoint through a Stochastic Process.Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives.Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancerSafety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access ProgramMorphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective StudyInnovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meetingCellular response upon proliferation in the presence of an active mitotic checkpointModulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitorsCombination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal AntibodiesImpact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs)Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study SubanalysisExploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME TrialSingle-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety ProfilesMetformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLCThe AURORA of a New Way to Value Myeloid Immunosuppression in CancerResistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectivesPhenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartmentMetabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical EvidenceDHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell LinesLKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial
P50
Q24297396-F42ED1A6-B9DC-415B-833A-2905F130F2FCQ26750748-0F5D2146-BDAD-47DC-9F61-4BA38F48A1C0Q30592319-9EB294F5-39B9-4A58-AD19-BB84CF364B95Q38377594-131D067E-EE65-41FC-B4FF-1CC345F28A63Q38674812-73B42A41-972B-4B73-84CE-95223A4406A5Q38706872-5BA7D2F8-8C45-4ED3-BB79-D43FFA27A794Q38738859-E1BF7149-A01D-4849-B072-71796BBAA91EQ38792334-DD644391-3E6F-42B4-9212-975C9EF377E3Q38879904-F6D11D6A-7D7B-4854-803B-3B2DEDBB4866Q39201601-B0ED9A56-97A3-44E6-9E31-DE3F86F311E4Q41236564-BD9AE1F4-809F-4E6A-A825-1026429C0CFCQ42246352-65F1CCD3-3244-439D-B223-FD8F4A1DCFE5Q46237998-1676808A-69B4-4F99-87BB-26C10B595898Q48274719-3669C819-E005-4B79-BACF-1232E58CD9BAQ51747406-2EC70B9F-9BDB-4E78-A657-233FF8330200Q56341979-131E3993-F113-40A4-87D4-AFE059E564A4Q56352627-3BEB0DBD-71F9-4B48-A4DC-3D5521FB5360Q56366469-32AF2EB3-9C5A-44AF-8783-374D6D1DC62BQ58590757-A1FC9E81-51F7-4576-AEBF-7CE0663DDFF8Q64062373-5293D336-F0D8-4916-A89C-4909C6FEA229Q64094662-321B42D8-885E-4400-8693-FC8CC4A88E48Q64242811-DD671460-2473-46F5-AA9E-EF735071DDFAQ90296046-A4D469F9-8BA0-44E7-BFA5-351DE2C639ECQ90870685-FA28B9DC-7DD6-4937-82D5-C026B2F24700Q90928136-D720AB89-ECB2-4DA3-8C36-2D5F814C1BE5Q91008953-1EF40A55-3E90-4089-8ECB-6E8DB83DCE6DQ91159351-67AA2AFD-3234-471E-931E-5852C39D1DC9Q91526628-DFF09A1E-5EFE-4230-8EB6-EA86F0A65EFEQ92190709-7D8453AC-1635-49B6-8D50-FFD62646DF57Q92380112-C94FBAEA-D78C-4C9A-8701-0C8903748125Q94582490-8635EB6C-CC67-4EEB-ACDF-380093EDA14EQ95304752-35B496B6-9705-40B5-8E57-ADDE9F0596B7Q95934747-0641DE43-E975-40A3-91B7-FF06578DD7DD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Claudio Vernieri
@ast
Claudio Vernieri
@en
Claudio Vernieri
@es
Claudio Vernieri
@nl
type
label
Claudio Vernieri
@ast
Claudio Vernieri
@en
Claudio Vernieri
@es
Claudio Vernieri
@nl
prefLabel
Claudio Vernieri
@ast
Claudio Vernieri
@en
Claudio Vernieri
@es
Claudio Vernieri
@nl
P1053
J-7426-2018
P106
P1153
42962495400
P21
P31
P4012
P496
0000-0003-1577-8176